Vancomycin Sodium Chloride Injection Recalled Due to Sterility Assurance Concerns
Central Admixture Pharmacy Services is recalling 11,338 bags of vancomycin sodium chloride injection nationwide due to FDA concerns about product sterility following an inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable product due to questioned sterility assurance following an FDA inspection. No illnesses, injuries, or confirmed contamination have been reported. The score is High (3) because the hazard involves a critical product attribute (sterility) without confirmed harm.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling vancomycin added to 0.9% sodium chloride injection (1.5 g/500 mL, 3 mg/mL) distributed nationwide. The recall affects 11,338 bags of this prescription medication across multiple lot numbers with expiration dates ranging from May 2023 through June 2023.
The recall was initiated after an FDA inspection called into question the sterility assurance of the product. Vancomycin is a sterile injectable antibiotic medication, and any compromise to sterility could pose a serious health risk to patients receiving the medication.
Healthcare facilities that received affected lots should cease use immediately and contact Central Admixture Pharmacy Services or the FDA with any questions. Specific lot numbers and expiration dates have been identified by the manufacturer. Patients should not stop taking prescribed vancomycin therapy but should consult with their healthcare provider or pharmacist about whether their medication may be affected by this recall.
The recalled product
- Product
- vancomycin added to 0.9% sodium chloride, 1.5 g/500 mL* (3 mg/mL), 500 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6176-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-883372
- 37-883387
- Exp 05/01/2023
- 37-883790
- Exp 05/02/2023
- 37-884160
- Exp 05/03/2023
- 37-885320
- 37-885321
- 37-885324
- Exp 05/08/2023
- 37-885921
- 37-885928
- 37-885930
- Exp 05/10/2023
- 37-886270
- Exp 05/11/2023
- 37-887511
- Exp 05/16/2023
- 37-887666
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27